TITLE PAGE

1

24

2 Manuscript Title: Awareness and use of Tranexamic Acid in the management of Postpartum Haemorrhage among health care providers in Enuqu, Nigeria. 3 4 5 Authors: Ogochukwu Onwujekwe¹, Adaobi Uchenna Mosanya^{2*}, Kingsley Ekwuazi³, Chukwuemeka Iyoke⁴. 6 7 1. Department of Pharmacy, University of Nigeria Teaching Hospital, Enugu, Nigeria 8 9 2. Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka. 3. Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu, 10 11 Nigeria. 12 4. Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu, 13 Nigeria. 14 15 *Corresponding author: Adaobi Uchenna Mosanya, Department of Clinical Pharmacy and Pharmacy 16 Management, University of Nigeria, Nsukka. 17 Faculty of Pharmaceutical Sciences building, Chime Avenue, University of Nigeria, Nsukka, Enugu 18 State, Nigeria. P.M.B. 410001 adaobi.mosanya@unn.edu.ng Tel: +234 8054 570 666 19 20 21 22 23

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

ABSTRACT Objectives: This study was carried out to determine the knowledge, practice and barriers regarding the use of Tranexamic acid for the prevention and treatment of postpartum hemorrhage among health care providers in Enugu, Nigeria. **Methods**: A cross sectional study was carried out among health professionals (Doctors, Pharmacists and Nurses) in two Nigerian tertiary teaching hospitals. One is Federal and the other is State. A total of 220 questionnaires were distributed, 207 were collected back (response rate: 94%) and analyzed using SPSS for inferential statistics with level of significance at p < 0.05. **Results**: Only 23.7% of the respondents had good Knowledge (p<0.001). Good awareness of the recent WHO recommendation on the use of Tranexamic acid for Postpartum Haemorrhage was low (19.8%, <0.001). Majority of the respondents have neither prescribed nor dispensed it (30%; <0.001). Very few respondents use it for all cases of Postpartum Haemorrhage (16.4%; p<0.001). Barriers against its use include non-awareness of the latest WHO recommendation, preference for other utero-tonics and cost of the drug. **Conclusions**: There was poor knowledge of Tranexamic acid, poor awareness of its recommendation and low use for Postpartum Haemorrhage among different cadres of health care providers. **Keywords:** Postpartum haemorrhage; Tranexamic acid; Maternal mortality; WHO; Nigeria. **Synopsis:** There was poor knowledge of Tranexamic acid, poor awareness of its recommendation and low use for Postpartum Haemorrhage among different cadres of health care providers.

Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Maternal mortality is a major public health issue and maternal related causes accounted for 10.7 million deaths 1990 and 20151. Globally an estimate of 303,000 maternal deaths occurred in 2015 mostly in the low resource settings, and most of them could have been prevented ¹ Nigeria has one of the highest ratios of maternal mortality in the world accounting for approximately 58,000 maternal deaths i.e. 19% globally ¹. One out of five causes of 70% of maternal mortality in Nigeria is hemorrhage ² In April, 2016, The World Maternal Antifibrinolytic trial (WOMAN) showed that showed Tranexamic acid when given early to women with Postpartum Haemorrhage could prevent one in three women from dying ³. As a consequence, the World Health Organization (WHO) published an updated recommendation on the use of Tranexamic acid (TXA) for Postpartum Haemorrhage treatment 4. Since then, several studies have been done to evaluate the safety and effectiveness (including cost-effectiveness) of Tranexamic acid for the prevention and treatment of postpartum hemorrhage, which may occur after vaginal as well as cesarean deliveries 5-14 Currently, there is no published study on the awareness of health care professionals regarding the use of Tranexamic acid for the prevention and management of Postpartum Haemorrhage in Nigeria. Therefore, this study aimed to determine the knowledge and practice of health care providers in Enugu Metropolis on the use of Tranexamic acid for the management of Postpartum Haemorrhage and the barriers to effective adoption and implementation of the new recommendation. The findings of the work is expected to have important implications for the delivery of high quality maternal care and prevention of maternal death through Postpartum Haemorrhage.

METHODS

72

73

78

Study design

- The study was a cross sectional study and data were collected using a structured pre
- tested questionnaire for health providers involved in obstetrics and Gynecology in both
- hospitals. The respondents were medical doctors, nurses and pharmacists. A
- consecutive sampling method was used in administering the questionnaires.

Study setting

- The study was carried out in Enugu metropolis. Enugu is the capital city of Enugu State.
- There are two tertiary public hospitals and several private hospitals (three of which are
- faith based). The inhabitants of Enugu are mostly civil servants, although the city is
- increasingly acquiring commercial activities. The population is comprised of mostly
- people who are mainly Igbo by tribe and Christian by religion. The study was carried out
- in Enugu State which has two tertiary teaching hospitals with Obstetrics and
- 85 Gynaecology units. Each of these centres records about 1000-3000 deliveries per
- annum. The study population comprised of healthcare providers (doctors, Pharmacists
- and nurses) working with the Obstetrics and Gynaecology units.

Sampling method

- A convenient sample of 220 questionnaires was administered to the respondents. A
- 90 proportionate allocation was used to get the sample of respondents in the two hospitals
- based on the population of appropriate healthcare providers in both hospitals. Hence,
- 145 was allocated to the Federal teaching hospital while 75 was to the State teaching
- 93 hospital.

94

Data collection instrument

A pre-tested structured questionnaire was used to collect data. The questionnaire was divided into 5 sections, the first section was on the Social demographic characteristics, the second was on Awareness and knowledge of respondents on the use of Tranexamic acid for Postpartum Haemorrhage (PPH) treatment and prevention, the third section was on provider practices, the fourth section was on the use of Tranexamic acid for Postpartum Haemorrhage and the last section was on acceptability and barriers to use of Tranexamic acid for Postpartum Haemorrhage.

Data collection and analysis

Copies of the questionnaire were distributed to the respondents by the researcher after a brief introduction of the research work, the purpose of the study and obtaining verbal consent from the prospective participants. Data collection began towards the end of 2019. However, it was interrupted by COVID-19 pandemic and the subsequent lockdown. It was finally concluded in 2021. Data was analyzed using Statistical Package for Social Sciences (SPSS) version 25 and Microsoft Excel 2019. The results from the data analysis were presented using descriptive and inferential statistics. Frequencies and percentages were used to summarize the items on the various sections of the questionnaire.

Outcome measurement

An overall knowledge/Awareness, Practice and Use was determined by scoring each correct response made by the respondents and summed them up to get the total score.

The score was categorized as good if (> 50%) and poor (<50%). The inferential statistics

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

-the Chi square Test of significance was used to assess the relationship between knowledge of Tranexamic acid and professions, institutions as well as the relationship between the use of Tranexamic acid and professions, institutions. The relationship was termed significant if p-value is less than .05 (p<.05). **Ethical Consideration** Ethical clearance was obtained from the ethical committee of the University of Nigeria Teaching Hospital and informed consent was obtained from all respondents before completing the questionnaire and those that declined were left out. RESULTS. A total of 207 questionnaires were returned and analyzed. This comprised of seventy (70) respondents (response rate: 93.33%) from the Enuqu state university teaching hospital and one hundred and thirty seven (137) respondents (response rate: 94.48%) from the University of Nigeria Teaching Hospital Ituku Ozalla, Enugu State. **Socio Demographic Characteristics** Approximately half (51.7%) of the respondents were medical doctors, 46.4 % were within the ages 30-39 years, while 57% were females (Table 1) Regarding their cadre, the doctors were mainly house officers (48.6%) while the pharmacists were mainly interns (29.5%) and the nurses were majorly staff nurses/midwives (56.4%). A greater percentage of the participants had bachelor's degree as their highest education level (67.6%) and those with less than 5 years of practice accounted for 39.6%.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

Knowledge on the Use of Tranexamic Acid for postpartum hemorrhage A good proportion of the respondents (85.5%) knew that post-partum haemorrhage associated deaths could be avoided by the use of prophylactic uterotonics during the third stage of labor (Table 2). However, very few (14%) knew that the conclusion of the Guideline Development Group meeting on the prevention and treatment of post-partum haemorrhage in March 2012 was that there was no direct evidence of the effectiveness and safety of tranexamic acid for post-partum haemorrhage. Knowledge of tranexamic acid as a synthetic lysine analog trans-4 aminoethylcyclo hexanecarboxylic acid was about average (50.2%); those who knew that the mechanism of action of tranexamic acid was by binding to plasminogen molecules, thereby blocking the binding of lysine to them were almost average (45.9%). In summary, the proportion of the respondents with good knowledge regarding the use of Tranexamic acid for Postpartum Haemorrhage was very low (Table 3) **Provider Practices of Tranexamic acid for postpartum hemorrhage** Some of the providers (28%) perceived that tranexamic acid should be used in all cases of post-partum haemorrhage regardless of if bleeding is due to genital tract trauma or other causes (Table 4). However, majority believed that tranexamic acid should be recognized as a life-saving intervention and made readily available for the management of Postpartum Haemorrhage in settings where obstetric care is provided (67.1%). Attitude on the use of Tranexamic acid for postpartum hemorrhage

Approximately a quarter of the respondents (21.7%) indicated the recommended dosage

regimen of 1g (100mg/ml) IV over 10 min (21.7%) and below average number (42.5%)

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

indicated that the effect of timing in administration of Tranexamic acid was very significant (Table 5). Indication of 1---3 hours after child birth as the best range of time to administer Tranexamic acid for optimal result was very poor (14.5%) while the indication that the use of tranexamic acid in women with contraindication to antifibrinolytic therapy not being a part of current routine care for Postpartum Haemorrhage treatment was about average (52.2%). Majority however perceived that Tranexamic acid should be considered as part of the standard postpartum haemorrhage treatment package (71.5%). Barriers against use of Tranexamic acid for postpartum hemorrhage There were various barriers identified as constraints to the use of Tranexamic acid by healthcare workers to manage Postpartum Haemorrhage. The most common barrier was ignorance about the latest recommendation by the WHO on the use of Tranexamic acid. The next most common barrier was preference for substitute drugs for the condition (Figure 1). Relationship profession, institution, knowledge of TXA for postpartum hemorrhage There was no significant relationship observed between profession and Institution with knowledge of the use of Tranexamic acid for postpartum hemorrhage (Table 6) Proportion of those with good knowledge between the different professions was comparable: medical doctor (22.4%), pharmacist (27.9%) and nurse/midwife (20.5%); and likewise between institutions: UNTH (25.5%) and ESUTH (20.0%). Relationship of profession, institution, use of TXA for postpartum hemorrhage

The use of Tranexamic acid for postpartum hemorrhage had significant relationship with both profession (p < .001) and institution (p < .001). Specifically, for profession, use of Tranexamic acid for postpartum hemorrhage was highest among pharmacists (61.8%) followed by medical doctors (44.0%) and the least was nurses/midwives (18.4%). More than half of the respondents from the UNTH (59.7%) used Tranexamic acid for postpartum hemorrhage unlike their counterparts in ESUTH (Table 7). In addition, there was a significant relationship between knowledge about the use of Tranexamic acid for postpartum hemorrhage and the use of it (p < .001). Those with good knowledge on the use (66.7%) were associated with the actual use far more than those with poor knowledge (37.2%). More specifically, the odds of use of Tranexamic acid for postpartum hemorrhage was 3.4 times [95% C.I- 1.67-6.84] higher among those with good knowledge than those with poor knowledge.

DISCUSSION

This study has the strength of being the first because there are no studies in published literature assessing the knowledge and use of Tranexamic acid for postpartum hemorrhage among health care providers. Majority of the surveyed health providers failed the definition of postpartum hemorrhage which is generally defined as blood loss of 500 ml and above after delivery through the vagina or blood loss of 1000 ml and above after delivery through cesarean section ¹⁵. Approximately, half of the respondents in this current study understood the mechanism of action of Tranexamic acid. Medical or health care professionals in gynecology should have the knowledge of the mechanism of action of Tranexamic acid. The mechanism of action of Tranexamic acid as explained by Cai and colleagues is brought about through blocking the binding site for lysine on

plasminogen molecules thereby preventing the association of plasminogen with already

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

formed plasmin and fibrin thus stopping rapid fibrinolysis of the formed fibrin mesh 16 There was poor use of Tranexamic acid and even among providers that use it, majority didn't know the recommended dose. An average proportion of the respondents were not sure of the appropriate dose of Tranexamic acid for the management of postpartum hemorrhage. In fact a minimal percentage of them got the correct dose which was a loading dose of 1 g (100 mg/mL) intravenously given at a rate of 1 mL/min ³ Tranexamic acid is one of the evidence-based approaches to reducing the incidence of adverse maternal outcomes associated with PPH. Other equally important approaches are prompt blood transfusion as well as active management of the third stage of labor ¹⁷. The proportion of the respondents who agreed that timing plays a significant role in the administration of Tranexamic acid were almost the same proportion as those who thought that immediate administration and 1-3 hours after birth put together. Those who thought that the administration of Tranexamic acid immediately after child birth was the best time range of Tranexamic acid for optimum outcome were much more that those who got the correct time range which was between 1 to 3 hours after child birth. In reality, the time range with evident advantage was between 1-3 hours. In fact it was observed that this timely administration significantly reduced the risk of mortality due to bleeding as well as the reliance on laparotomy for bleeding control ³. The poor knowledge and use observed in this current study could be attributed to not being updated on current guidelines and also lack of advocacy and training of health professional. Importance of training can never be over emphasized regarding emergency obstetrics response. There

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

is evidence that trainings aimed to improve clinical knowledge and skills with respect to the risk factors of postpartum hemorrhage prevents maternal morbidity and mortality¹⁷. Few respondents have recommended, dispensed or administered and actually used it in practice despite recognizing it as a lifesaving intervention that should be made available for the management of Tranexamic acid in Obstetrics practice. They were more likely to use it for other cases of bleeding than postpartum hemorrhage. It shows that there is still room for greater awareness to be created for the use of Tranexamic acid in postpartum hemorrhage management. Possible avenues include clinical meetings and continuous professional development sessions. This suboptimal practice could also be as a result of not being updated on the most current guideline. Perhaps other reasons could be related to the barriers against its use as observed in this current study. Some of the perceived barriers were ignorance of the latest recommendation, preference to other uterotonics, high cost of drug, and fear of thromboembolic event and drug scarcity. One of the barriers identified in this study against the optimal use of Tranexamic acid for the management of postpartum hemorrhage was high cost of the former. It is important to highlight here some of the outcomes from cost-effectiveness studies done on the use of Tranexamic acid for postpartum hemorrhage. Li Bernadette and colleagues calculated the incremental cost-effectiveness ratios (ICER) of treating postpartum hemorrhage within 3 hours of giving birth with or without Tranexamic acid. Results generated were optimistic. Despite the possibility of increasing the relative risk of death due to bleeding while on Tranexamic acid to the upper bound of 0.91, the ICER was \$ 692 per Qualityadjusted life-Years (QALY). In addition, if the discount rate was applied as high as 10%, the ICER (\$ 507 per QALY) was still within the threshold range of Nigeria (\$ 446 - \$ 2880

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

per QALY) i.e. within the cost-effective range. In summary, at the lower threshold range (\$ 446 per QALY) the probability that Tranexamic acid is cost-effective is 93% ¹⁸ This is comparable with the results from a more recent study in a developed country ⁶ CONCLUSION The findings show that there is poor knowledge about the use of WHO recommended Tranexamic acid for postpartum hemorrhage among different cadres of healthcare workers. The uptake of the recommendation among health workers was rather low and seriously affecting its use. Most health providers have a poor awareness of the recommendation which led to a poor practice and use. **RECOMMENDATIONS** A major limitation of this study was the cross sectional design adopted. Therefore there is need for prospective studies which would provide a more robust evidence on the cost effectiveness of Tranexamic acid for postpartum hemorrhage. This will provide basis for the advocacy by policy makers targeting professionals and updating them on current best practices and also alleviating their fears. The authors declare no conflict of interest There was no external funding for this study **Authors' contribution** Kingslev Ekwuazi. Ogochukwu Onwujekwe. Adaobi Conceptualization: Mosanya & Chukwuemeka Iyoke

Data Curation: Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya & 285 Chukwuemeka Iyoke 286 Formal analysis: Ogochukwu Onwujekwe & Adaobi Uchenna Mosanya 287 Methodology: Kingsley Ekwuazi & Ogochukwu Onwujekwe 288 Supervision: Chukwuemeka Iyoke 289 Writing – orginal draft: Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya, 290 Kingsley Ekwuazi & Chukwuemeka Iyoke 291 Writing – review & editing: Ogochukwu Onwujekwe, Adaobi Uchenna Mosanya, 292 Kingsley Ekwuazi & Chukwuemeka Iyoke 293 294 295 REFERENCES 1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: A WHO 296 systematic analysis. Lancet Glob. Health. 2014;2(6). doi:10.1016/S2214-297 109X(14)70227-X 298 2. Piane GM. Maternal Mortality in Nigeria: A Literature Review. World Med. Health 299 Policy. 2019;11(1):83-94. doi:10.1002/wmh3.291 300 3. Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration 301 on mortality, hysterectomy, and other morbidities in women with post-partum 302 haemorrhage (WOMAN): an international, randomised, double-blind, placebo-303 controlled trial. Lancet. 2017;389(10084):2105-2116. doi:10.1016/S0140-304 305 6736(17)30638-4 World Health Organization. Updated WHO Recommendation on Tranexamic Acid 306 4. for the Treatment of Postpartum Haemorrhage: Highlights and Key Messages from 307

the World Health Organization's 2017 Global Recommendation. 2017;(October):5. 308 5. Sudhof LS, Shainker SA, Einerson BD. Tranexamic acid in the routine treatment of 309 postpartum hemorrhage in the United States: a cost-effectiveness analysis. Am. J. 310 311 Obstet. Gynecol. 2019;221(3):275.e1-275.e12. doi:10.1016/j.ajog.2019.06.030 Howard DC, Jones AE, Skeith A, Lai J, D'Souza R, Caughey AB. Tranexamic acid 6. 312 for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. Am. J. 313 Obstet. Gynecol MFM. 2022;4(3):100588. doi:10.1016/j.ajogmf.2022.100588 314 7. Modir H. Moshiri E. Naseri N. Faraii F. Almasi-Hashiani A. A randomized parallel 315 design trial of the efficacy and safety of tranexamic acid, dexmedetomidine and 316 nitroglycerin in controlling intraoperative bleeding and improving surgical field 317 quality during septorhinoplasty under general anesthesia. Med. Gas Res. 318 2021;11(4):131-137. doi:10.4103/2045-9912.318857 319 8. Wong J, George RB, Hanley CM, Saliba C, Yee DA, Jerath A. Tranexamic acid: 320 current use in obstetrics, major orthopedic, and trauma surgery. Can J Anaesth 321 2021;68(6):894-917. doi:10.1007/s12630-021-01967-7 322 Franchini M, Mengoli C, Cruciani M, et al. Safety and efficacy of tranexamic acid 323 9. for prevention of obstetric haemorrhage: An updated systematic review and meta-324 analysis. Blood Transfus. 2018;16(4):329-337. doi:10.2450/2018.0026-18 325 10. Eyeberu A, Getachew T, Amare G, et al. Use of tranexamic acid in decreasing 326 327 blood loss during and after delivery among women in Africa: a systematic review and meta-analysis. Arch. Gynecol. Obstet.. 2022;(0123456789). 328 doi:10.1007/s00404-022-06845-1 329

Wang K, Santiago R. Tranexamic acid – A narrative review for the emergency 330 11. medicine clinician. Am. J. Emerg. Med. 2022;56:33-44. 331 doi:10.1016/j.ajem.2022.03.027 332 Van Houwe M, Roofthooft E, Van de Velde M. The role of tranexamic acid in 333 12. obstetric hemorrhage: a narrative review. Acta Anaesthesiol. Belg. 2022;73(2):103-334 335 108. doi:10.56126/73.2.12 Bouthors AS, Gilliot S, Sentilhes L, et al. The role of tranexamic acid in the 13. 336 management of postpartum haemorrhage. Best Pract. Res. Clin. Anaesthesiol. 337 2022;36:411-426. doi:10.1016/j.bpa.2022.08.004 338 14. Bellos I, Pergialiotis V. Tranexamic acid for the prevention of postpartum 339 hemorrhage in women undergoing cesarean delivery: an updated meta-analysis. 340 Am. J. Obstet. Gynecol. 2022;226(4):510-523.e22. doi:10.1016/j.ajog.2021.09.025 341 15. Smith JR. Medscape. Postpartum Hemorrhage. 342 https://emedicine.medscape.com/article/275038-print. Published 2022. Accessed 343 January 16, 2023. 344 Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: An overview of 345 16. the clinical indications for TXA in medical and surgical patients. Eur. J. Haematol. 346 2020;104(2):79-87. doi:10.1111/ejh.13348 347 17. Cooper N, O'Brien S, Siassakos D. Training health workers to prevent and manage 348 349 post-partum haemorrhage (PPH). Best Pract Res Clin Obstet Gynaecol 2019;61(November 2019):121-129. doi:10.1016/j.bpobgyn.2019.05.008 350

Li B, Miners A, Shakur H, Roberts I. Tranexamic acid for treatment of women with 18. post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. Lancet Glob. Health 2018;6(2):e222-e228. doi:10.1016/S2214-109X(17)30467-9

Table 1: Demographic Characteristics of the Health Professionals

		Frequency	Percent
Age	<30	66	31.9
G	30-39	96	46.4
	40-49	36	17.4
	50-59	8	3.9
	≥ 60	1	0.5
Sex	Male	89	43.0
	Female	118	57.0
Profession	Medical doctor	107	51.7
	Pharmacist	61	29.5
	Nurse/midwife	39	18.8
Medical Doctors' cadre	House officer	52	48.6
(n=107)	Registrar	44	41.1
	Senior registrar	5	4.7
	Consultant	6	5.6
Cadre of Pharmacists	Intern	18	29.5
(n=61)	Senior pharmacist	12	19.7
	Principal pharmacist	12	19.7
	Chief pharmacist	8	13.1
	Assistant director	9	14.8
	Deputy director	2	3.3
Nurses' cadre	Intern	2	5.1
(n=39)	Staff nurse/midwife	22	56.4
	Senior nursing officer	8	20.5
	PNO	1	2.6
	Matron	3	7.7
	CNO	1	2.6
	Senior matron	2	5.1
Highest level of educat		40	0.0
	Diploma	13	6.3
	Bachelors/1st degree	140	67.6
	Master's degree	24	11.6
	Professional fellowship	22	10.6
Voore of practice in pre	No response	8	3.9
Years of practice in pro		82	39.6
	< 5 5-10	70	
	11-15	70 27	33.8 13.0
	16-20	13	6.3
	21-25		1.4
	26-30	3 3	1.4
	> 30	3	1.4
	> 30 No response	5 6	2.9
	ino iespolise	U	۷.5

Table 2: Knowledge about use of tranexamic acid for postpartum haemorrhage

	Yes	No	Don't know	Chi- Square	P- value
Postpartum hemorrhage is defined as blood loss of 1000ml or more within 24 hours after birth	157(75.8)	40(19.3) a	10(4.8)	174.870	<.001
Majority of PPH associated deaths could be avoided by the use of prophylactic uterotonics during the third stage of labour	^a 177(85.5)	5(2.4)	25(12.1)	256.464	<.001
The Guideline Development Group meeting on the prevention and treatment of PPH in March 2012 concluded there was no direct evidence of the effectiveness and safety of TXA for PPH	29(14.0) ^a	43(20.8)	135(65.2)	96.116	<.001
TXA is a synthetic lysine analog trans-4 aminoethylcyclohexanecarboxyli c acid	^a 104(50.2)	3(1.4)	100(48.3)	94.812	<.001
The mechanism of action of TXA is by binding to plasminogen and thereby blocking activation to plasmin leading to inhibition of fibrinolysis and fibrinogenolysis	95(45.9) ^a	32(15.5)	80(38.6)	31.391	<.001
The April 2017 world maternal anti-fibrinolytic (WOMAN) trial supersedes the March 2012 trial	52(25.1) ^a	3(1.4)	152(73.4)	167.159	<.001
The woman trial for PPH concluded on oral and intravenous administration of TXA for PPH	83(40.1)	11(5.3) ^a	113(54.6)	79.652	<.001
PPH is a leading cause of maternal mortality with about one quarter of all maternal deaths associated with it in low income countries	^a 184(88.9)	3(1.4)	20(9.7)	289.594	<.001

aindicates the right responses- correct knowledge or use

Table 3: The categorized knowledge score about use of TXA for PPH

				Chi-	
			Perce	Squar	P-
		Frequency	nt	е	Value
Good	(Knowledge score > 50%)	49	23.7	57.40	<.001
Poor	(Knowledge score ≤ 50%)	158	76.3		

Table 4: Provider's use of TXA for PPH

	Yes	No	Don't know	Chi- Square	P- value
TXA should be used in all cases of PPH regardless of if bleeding is due to genital tract trauma or other causes	58(28.0) ^a	86(41.5)	63(30.4)	6.46	.039
Have you recommended/dispensed TXA for the management or prevention of PPH?	62(30.0) ^a	129(62.3)	16(7.7)	93.59	<.001
Do you use TXA in all cases of PPH regardless of if bleeding is due to genital tract trauma or other causes?	34(16.4) ^a	160(77.3)	13(6.3)	183.22	<.001
Do you recognize TXA as a life-saving intervention for managing PPH in obstetrics practice?	^a 155(74.9)	38(18.4)	14(6.8)	164.96	<.001
Have you used TXA for other cases of bleeding or haemorrhage other than for PPH?	74(35.7) ^a	102(49.3)	31(15.0)	37.07	<.001

aindicates the right responses- correct knowledge or use

		Frequency	Percent		P- Value
Do vo	ou use/dispense tranexamic acid for the			2.74	.09
-	gement of post-partum haemorrhage in			2.14	.03
	facility?				
	es ^a	85	41.1		
- N		108	52.2		
	o response	14	6.8		
	mmended dosage regimen used for	14	0.0	239.06	<.001
	xamic acid in PPH treatment?			239.00	<.001
		19	9.2		
	g (200mg/ml) IV over 10 min				
	g (300mg/ml) IV over 20 min	14	6.8		
	g (100mg/ml) IV over 10 min ^a	45	21.7		
	g (400mg/ml) IV over 10 min	3	1.4		
	Oon't know	126	55.6		004
	is the effect of timing in the			71.51	<.001
	nistration of tranexamic acid for post-				
•	m haemorrhage				
	lot significant	4	1.9		
	'ery significant ^a	88	42.5		
	lot sure	53	25.6		
	Oon't know	62	28.5		
	is the best range of time to administer			256.10	<.001
trane	xamic acid for optimal result				
- Ir	mmediately after child birth	58	28.0		
- 1	-3 hours after child birtha	30	14.5		
- 4	-6 hours after child birth	6	2.9		
- 7	-10 hours after child birth	2	1.0		
- >	10 hours after child birth	3	1.4		
- D	Oon't know	108	52.2		
Whic	h of these is not a part of the current			138.34	<.001
	ne care for PPH treatment?				
	luid replacement	20	9.7		
	Surgical interventions	24	11.6		
	Ise of tranexamic acid in women with	108	52.2		
	ontraindication to antifibrinolytic therapy ^a	100	02.2		
	Monitoring vital signs	36	17.4		
	lo response	19	9.2		
	examic acid should be considered as	10	J.Z	57.87	<.001
				57.07	<.001
•	of the standard PPH treatment package?	72	25.2		
	strongly agree ^a	73 75	35.3		
	agree ^a	75 7	36.2		
	Disagree	7	3.4		
- L	Oon't know	52	25.1		

Table 6: Relationship between Profession, Institution and Knowledge of TXA for PPH

	Knowledge on Use of TXA for PPH				
	Good (n = 49)	Poor (n = 158)	Total (n = 207)	Chi- Square	p- value
Medical doctor	24(22.4)	83(77.6)	107	.901	.637
Pharmacist	17(27.9)	44(72.1)	61		
Nurse/midwife	8(20.5)	31(79.5)	39		
UNTH	35(25.5)	102(74.5)	137	.789	.374
ESUTH	14(20.0)	56(80.0)	70		
	doctor Pharmacist Nurse/midwife UNTH	TXA for PR Good (n = 49) Medical 24(22.4) doctor Pharmacist 17(27.9) Nurse/midwife 8(20.5) UNTH 35(25.5)	TXA for PPH Good Poor (n = 49) (n = 158) Medical 24(22.4) 83(77.6) doctor Pharmacist 17(27.9) 44(72.1) Nurse/midwife 8(20.5) 31(79.5) UNTH 35(25.5) 102(74.5)	TXA for PPH Good Poor Total (n = 49) (n = 158) (n = 207) Medical 24(22.4) 83(77.6) 107 doctor Pharmacist 17(27.9) 44(72.1) 61 Nurse/midwife 8(20.5) 31(79.5) 39 UNTH 35(25.5) 102(74.5) 137	TXA for PPH Good (n = 49) Poor (n = 158) Chi-Square 207) Medical 24(22.4) 83(77.6) 107 .901 doctor Pharmacist 17(27.9) 44(72.1) 61 Nurse/midwife 8(20.5) 31(79.5) 39 UNTH 35(25.5) 102(74.5) 137 .789

Table 7: Relationship between Profession, Institution and Use of TXA for PPH

		Use of TXA for					
		Postpartum					
		hemorrhage					
		Yes	No	Total	Chi-	p-	
		(n = 85)	(n =	(n =	Square	value	
			108)	207)			
Profession	Medical	44(44.0)	56(56.0)	100	17.174	<	
	doctor					.001	
	Pharmacist	34(61.8)	21(38.2)	55			
	Nurse/midwife	7(18.4)	31(81.6)	38			
Institution	UNTH	74(59.7)	50(40.3)	124	34.407	<	
						.001	
	ESUTH	11(15.9)	58(84.1)	69			